Recent News

• 09.08.2025 - Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
• 09.02.2025 - Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference
• 08.18.2025 - Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
• 07.10.2025 - Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
• 07.02.2025 - Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

Recent Filings

• 05.01.2024 - POS AM Post-Effective amendments for registration statement
• 05.01.2024 - POS AM Post-Effective amendments for registration statement
• 05.01.2024 - POS AM Post-Effective amendments for registration statement
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - EFFECT Notice of Effectiveness
• 05.01.2024 - POS AM Post-Effective amendments for registration statement
• 05.01.2024 - POS AM Post-Effective amendments for registration statement